Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-18T01:14:09.820Z Has data issue: false hasContentIssue false
  • English
  • Français

Switching to amisulpride monotherapy for treatment-resistant schizophrenia

Published online by Cambridge University Press:  16 April 2020

V.P. Kontaxakis ,
B.J. Havaki-Kontaxaki ,
P.P. Ferentinos ,
K.G. Paplos  and
C.R. Soldatos
V.P. Kontaxakis*
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
B.J. Havaki-Kontaxaki
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
P.P. Ferentinos
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
K.G. Paplos
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
C.R. Soldatos
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
*
⁎Corresponding author. Tel.: +30 210 728 9257; fax: +30 210 724 2020. E-mail address: bkont@cc.uoa.gr (V.P. Kontaxakis).
Get access

Abstract

The objective of this study was to assess switching to amisulpride (AMS) in treatment-resistant schizophrenia. Seven male subjects were switched to AMS and followed for 8 weeks. PANSS scores improved from 123 to 66 over this period. We conclude that AMS is of interest in the treatment of refractory schizophrenia.

Keywords

SchizophreniaAntipsychoticsTreatment resistanceAmisulpride
Type
Short communication
Information
European Psychiatry , Volume 21 , Issue 3 , April 2006 , pp. 214 - 217

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agelink, M.W., Kavuk, I., Ak, I.Clozapine with amisulpride for refractory schizophrenia. Am. J. Psychiatry 2004;161:924–925.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association; 1994.Google Scholar
Buckley, P., Miller, A., Olsen, J., Garver, D., Miller, D.D., Csernansky, J.When symptoms persist: clozapine augmentation strategies. Schizophr. Bull 2001;27:615–628.CrossRefGoogle ScholarPubMed
Citrome, L., Bilder, R.M., Volavka, J.Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. Journal of Psychiatric Practice 2002;8:205–215.CrossRefGoogle ScholarPubMed
Croissant, B., Hermann, D., Olbrich, R.Reduction of side effects by combining clozapine with amisulpride: case report and short review of clozapine-induced hypersalivation—a case report. Pharmacopsychiatry 2005;38:38–39.CrossRefGoogle ScholarPubMed
Davis, J.M., Chen, N., Glick, I.D.A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003;60:553–564.CrossRefGoogle ScholarPubMed
Guy, W., editors. ECDEU assessment manual for psychopharmacology. Rockville: MD, US Department of Health, Education and Welfare; 1976.Google Scholar
Kane, J., Honigfeld, G., Singer, J., Meltzer, H.and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988;45:789–796.CrossRefGoogle Scholar
Kay, S.R., Fiszbein, A., Opler, L.A.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull 1987;13:261–276.CrossRefGoogle Scholar
Kontaxakis, V.P., Ferentinos, P.P., Havaki-Kontaxaki, B.J., Paplos, K.G., Roukas, D.K., Christodoulou, G.N.Case studies of adjunctive agents in clozapine-resistant schizophrenic patients. Clin. Neuropharmacol 2005;28:50–53.CrossRefGoogle ScholarPubMed
Lehman, A.F., Lieberman, J.A., Dixon, L.B., McGlashan, T.H., Miller, A.L., Perkins, D.O.et al.American Psychiatric Association. Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edition. Am. J. Psychiatry 2004;161(2 Suppl):1–56.Google Scholar
Lerner, V., Bergman, J., Borokhov, A., Loewenthal, U., Miodownik, C.Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin. Neuropharmacol 2005;28:66–71.CrossRefGoogle ScholarPubMed
Meltzer, H.Y., Burnett, S., Bastani, B., Ramirez, L.F.Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990;41:892–897.Google ScholarPubMed
Miller, A.L., Chiles, J.A., Chiles, J.K., Crismon, M.L., Rush, A.J., Shon, S.P.The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J. Clin. Psychiatry 1999;60:649–657.CrossRefGoogle ScholarPubMed
Moller, H.J.Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003;27:1101–1111.10.1016/j.pnpbp.2003.09.006CrossRefGoogle ScholarPubMed
Mortimer, A., Martin, S., Loo, H., Peuskens, J.SOLIANOL Study Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int. Clin. Psychopharmacol 2004;19:63–69.CrossRefGoogle Scholar
Mortimer, A.M.How do we choose between atypical antipsychotics? The advantages of amisulpride. Int. J. Neuropsychopharmacol. 2004;7(Suppl 1):S21–5.CrossRefGoogle ScholarPubMed
Munro, J., Matthiasson, P., Osborne, S., Travis, M., Purcell, S., Cobb, A.M.et al.Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand 2004;110:292–298.CrossRefGoogle ScholarPubMed
National Institute of Clinical Excellence. London: Health technology appraisal no. 43, NICE; 2002.Google Scholar
Sechter, D., Peuskens, J., Fleurot, O., Rein, W., Lecrubier, Y.Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;27:1071–1081.10.1016/S0893-133X(02)00375-5CrossRefGoogle Scholar
Seeman, P.Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002;47:27–38.CrossRefGoogle ScholarPubMed
Zink, M., Henn, F.A., Thome, J.Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur. Psychiatry 2004;19:56–58.CrossRefGoogle ScholarPubMed
Zink, M., Knopf, U., Henn, F.A., Thome, J.Combination of clozapine and amisulpride in treatment-resistant schizophrenia—case reports and review of the literature. Pharmacopsychiatry 2004;37(1):26–31.Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.